ArticleEMBO molecular medicine2018

Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.

Ileabett M Echevarría-Vargas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.